Patents Examined by Gary B. Nickol
  • Type I interferon receptor antibody and use thereof
    Patent number: 11136399
    Abstract: The present disclosure discloses monoclonal antibodies binding to type I interferon alpha receptor and their uses. The antibodies are capable of inhibiting the biological activity of type I interferons, and can be used for treating, preventing, or diagnosing the diseases mediated by the type I interferons. Also provided are immunoconjugate, bispecific molecule and pharmaceutical compositions comprising the antibodies of the present disclosure.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: October 5, 2021
    Assignee: INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCES
    Inventors: Liguo Zhang, Lishan Su, Jingyun Li, Jianping Ma
  • Compositions comprising bacterial strains
    Patent number: 11123378
    Abstract: The invention provides compositions comprising bacterial strains for treating and preventing brain injury.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: September 21, 2021
    Assignee: 4D Pharma Research Limited
    Inventors: Helene Savignac, Imke Elisabeth Mulder, Alexander James Stevenson
  • CRISPR-CAS system for a yeast host cell
    Patent number: 11118193
    Abstract: The present invention relates to the field of molecular biology and cell biology. More specifically, the present invention relates to a CRISPR-CAS system for a yeast host cell.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: September 14, 2021
    Assignee: DSM IP ASSESTS B.V.
    Inventors: René Verwaal, Bernard Meijrink, Nathalie Wiessenhaan, Brenda Vonk, Johannes Andries Roubos
  • Anti-IL-5 antibodies
    Patent number: 11111292
    Abstract: Disclosed herein are fully human antibody molecules that immunospecifically bind to human IL-5. The antibody molecules can bind to human IL-5 with an equilibrium affinity constant (KD) of at least about 40 pM as determined by surface plasmon resonance.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: September 7, 2021
    Assignee: CEPHALON, INC.
    Inventors: Mark Terence Liddament, Anthony Doyle, Adam Clarke, David Jose Simon Laine, Bridget Ann Cooksey
  • Anti-canine TARC antibody used for treatment and diagnosis of canine atopic dermatitis
    Patent number: 11104727
    Abstract: Provided are an anti-canine TARC antibody for use in the treatment and diagnosis of canine atopic dermatitis, and a method for treating or diagnosing canine atopic dermatitis using the same. An anti-canine TARC monoclonal antibody binding to canine TARC, comprising a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 2 and a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 4, or a functional fragment thereof binding to canine TARC.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: August 31, 2021
    Assignee: NIPPON ZENYAKU KOGYO CO., LTD.
    Inventors: Toshihiro Tsukui, Miyuki Kageyama, Masahiro Kato, Rieko Suzuki
  • Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
    Patent number: 11091543
    Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: August 17, 2021
    Assignee: Swedish Orphan Biovitrum AG
    Inventors: Cristina de Min, Walter Ferlin, Fabrizio De Benedetti
  • IL-11R? antibodies
    Patent number: 11084878
    Abstract: Provided are antigen-binding molecules capable of binding to IL-11R?, and methods of medical treatment and prophylaxis using the same.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: August 10, 2021
    Assignees: National University of Singapore, Singapore Health Services PTE LTD., Boehringer Ingelheim International GmbH
    Inventors: Stuart Alexander Cook, Sebastian Schaefer
  • Targeted mutant interferon-gamma and uses thereof
    Patent number: 11084859
    Abstract: The present invention relates, in part, to chimeric proteins comprising mutant interferon-? and their use as therapeutic agents.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: August 10, 2021
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Nikolai Kley, Jan Tavernier, Frank Peelman, Lennart Zabeau
  • IL-11 antibodies
    Patent number: 11084874
    Abstract: Provided are antigen-binding molecules capable of binding to IL-11, and methods of medical treatment and prophylaxis using the same.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: August 10, 2021
    Assignees: Singapore Health Services PTE LTD., National University of Singapore, Boehringer Ingelheim International GmbH
    Inventors: Stuart Alexander Cook, Sebastian Schaefer
  • IL-11 antibodies
    Patent number: 11078268
    Abstract: IL-11 antibodies are disclosed. Also disclosed are compositions comprising the IL-11 antibodies, and methods using the IL-11 antibodies.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: August 3, 2021
    Assignees: Singapore Health Services PTE LTD, National University of Singapore
    Inventors: Stuart Alexander Cook, Sebastian Schaefer
  • CD80 variant immunomodulatory proteins and uses thereof
    Patent number: 11078282
    Abstract: Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: August 3, 2021
    Assignee: ALPINE IMMUNE SCIENCES, INC.
    Inventors: Ryan Swanson, Michael Kornacker
  • Cancer treatment
    Patent number: 11078289
    Abstract: The invention relates generally to the treatment of cancer. One embodiment of the invention provides a method of treating cancer in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: August 3, 2021
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
  • Biological marker for evaluating the IL-17 pro-inflammatory functional contribution dependent level in an individual
    Patent number: 11079391
    Abstract: The invention relates to an in vitro process for determining the functional IL-17 pro-inflammatory dependent level (IPDL) of a biological sample, comprising the following steps: a) measuring the level of an inflammatory marker produced by IL-17-sensitive cells incubated in the presence of a biological sample, b) measuring the level of said inflammatory marker produced by said cells incubated in the presence of a biological sample, in the presence of antibodies which neutralize the biological activity of IL-17, and c) determining the IPDL level, which is the difference between the level of said inflammatory marker measured in step a) and the level of said inflammatory marker measured in step b).
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: August 3, 2021
    Assignees: Hospices Civils de Lyon, Universite Claude Bernard Lyon 1
    Inventors: Pierre Miossec, Ndieme Thiam
  • Combined enteropathogen recombinant construct
    Patent number: 11077200
    Abstract: The inventive subject matter relates to a construct comprising antigens derived from multiple enterobacteria including Campylobacter jejuni capsule polysaccharide polymer, enterotoxigenic Escherichia coli recombinant polypeptide construct and lipopolysaccharide from Shigella spp. The subject invention also relates to a method of inducing an immune response utilizing the inventive composition.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: August 3, 2021
    Assignee: The United States of America as Represented by the Secretary of the Navy
    Inventors: Patricia Guerry, Mario Artur Monteiro, Stephen Savarino
  • Anti-human IL-3 antibodies, their use in treatment of a disease or malfunction associated with elevated expression or levels of IL-3, and their use in a method to detect human IL-3
    Patent number: 11078266
    Abstract: Anti-human interleukin 3 (IL-3) antibodies or fragments thereof according to the present invention are useful as therapeutic agents. The antibodies can be used in pharmaceutical compositions for the treatment or prevention of diseases which are associated with elevated expression or levels of human IL-3 in a patient, especially inflammatory or autoimmune diseases, such as rheumatoid arthritis. The antibodies can also be used to detect human IL-3 expressed by human cells.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: August 3, 2021
    Assignee: Universitätsklinikum Regensburg
    Inventors: Matthias Mack, Hilke Bruhl, Kerstin Renner
  • IL-11R? antibodies
    Patent number: 11078269
    Abstract: IL-11R? antibodies are disclosed. Also disclosed are compositions comprising the IL-11R? antibodies, and methods using the IL-11R? antibodies.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: August 3, 2021
    Assignees: Singapore Health Services PTE LTD, National University of Singapore
    Inventors: Stuart Alexander Cook, Sebastian Schaefer
  • Interferon receptor 1 antibodies and their uses
    Patent number: 11072664
    Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: July 27, 2021
    Assignee: E.R. Squibb & Sons, L.L.C.
    Inventors: Josephine M. Cardarelli, Alison Witte, Mohan Srinivasan
  • Production of soluble recombinant protein without n-terminal methionine
    Patent number: 11060123
    Abstract: The present invention is directed to the cells, compositions and methods for the production of recombinant protein, wherein an f-met group on the 5?-terminus is enzymatically removed. In particular, the invention is directed to a production process for obtaining high levels of soluble recombinant CRM197 protein from E. coli. Cells preferably contain one or more mutations of disulfide reductase genes, so that disulfide reductase activity is reduced. The invention also relates to purification method for CRM197 as well as characterization of properly folded CRM197 protein.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: July 13, 2021
    Assignee: Fina BioSolutions, LLC
    Inventors: Natalia Oganesyan, Andrew Lees, Min-Ju Chang
  • Anti-IFNAR1 antibodies for treating autoimmune diseases
    Patent number: 11059897
    Abstract: Provided are antibodies or fragments thereof having binding specificity to the human interferon alpha and beta receptor subunit 1 (IFNAR1) protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as provided, or variants thereof. Methods of using the antibodies or fragments thereof for treating autoimmune diseases and disorders are also provided.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: July 13, 2021
    Assignee: I-Mab Biopharma US Limited
    Inventors: Wei Cao, Weili Xu
  • Vaccine for protection against ETEC-induced diarrhea comprising dmLT
    Patent number: 11052143
    Abstract: An oral vaccine for immunization against ETEC-induced diarrhea, comprising inactivated Escherichia coli cells expressing an ETEC colonization factor antigen and dmLT protein adjuvant, wherein the vaccine preferably comprises less than 1013 cells per unit dose.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: July 6, 2021
    Assignee: SCANDINAVIAN BIOPHARMA HOLDING AB
    Inventors: Ann-Mari Svennerholm, Joshua Tobias, Nils Carlin, Jan Holmgren